Home    Back

Alicaforsen    (DrugBank: Alicaforsen)

2 diseases
IDDisease name (Link within this page)Number of trials
96Crohn disease2
97Ulcerative colitis2

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,209 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00048295
(ClinicalTrials.gov)		May 200229/10/2002Alicaforsen (ISIS 2302) in Patients With Active Crohn’s DiseaseISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn’s DiseaseCrohn's DiseaseDrug: AlicaforsenIsis PharmaceuticalsNULLActive, not recruiting12 YearsN/ABoth150Phase 3Belgium;Czech Republic;Germany;Italy;Poland;Spain
2NCT00048113
(ClinicalTrials.gov)		September 200124/10/2002Alicaforsen (ISIS 2302) in Patients With Active Crohn's DiseaseISIS 2302-CS20, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's DiseaseCrohn's DiseaseDrug: AlicaforsenIsis PharmaceuticalsNULLCompleted12 YearsN/ABoth150Phase 3United States;Canada

97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,269 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00063414
(ClinicalTrials.gov)		September 200325/6/2003ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative ColitisISIS 2302-CS22, Phase II, Double-Blinded, Active-Controlled Study of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis (Left-Sided Colitis or Pancolitis With Left Sided Disease Flare)Ulcerative ColitisDrug: AlicaforsenIsis PharmaceuticalsNULLCompleted18 YearsN/ABothPhase 2United States
2NCT00063830
(ClinicalTrials.gov)		June 20037/7/2003ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.ISIS 2302-CS27, Phase 2, Double-Blinded, Controlled Study of Four Dosing Regimens of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative ColitisUlcerative ColitisDrug: AlicaforsenIsis PharmaceuticalsNULLCompleted18 YearsN/ABothPhase 2United States